A New Rapid-Acting Antidepressant.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32243798.
- Also identified by DOI 10.1016/j.cell.2020.02.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Antidepressive Agents
- Depressive Disorder, Treatment-Resistant
- Drug Approval
- Ketamine
- Receptors, N-Methyl-D-Aspartate